Problems with patents

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Problems with patents

Postby dignan » Tue Mar 13, 2007 10:47 am

This is a really interesting column on the shortcoming of the patent system in the pharmaceutical industry. It isn't written by Joe-average blogger, it is written by Nobel prize winner and former chief economist of the World Bank, Joseph Stiglitz.

Prizes, Not Patents

Part of modern medicine’s success is built on new drugs, in which pharmaceutical companies invest billions of dollars on research. The companies can recover their expenses thanks to patents, which give them a temporary monopoly and thus allow them to charge prices well above the cost of producing the drugs. We cannot expect innovation without paying for it. But are the incentives provided by the patent system appropriate, so that all this money is well spent and contributes to treatments for diseases of the greatest concern? Sadly, the answer is a resounding “no.”

The fundamental problem with the patent system is simple: it is based on restricting the use of knowledge. Because there is no extra cost associated with an additional individual enjoying the benefits of any piece of knowledge, restricting knowledge is inefficient. But the patent system not only restricts the use of knowledge; by granting (temporary) monopoly power, it often makes medications unaffordable for people who don’t have insurance. In the Third World, this can be a matter of life and death for people who cannot afford new brand-name drugs but might be able to afford generics. For example, generic drugs for first-line AIDS defenses have brought down the cost of treatment by almost 99% since 2000 alone, from $10,000 to $130.

But, despite the high price they pay, developing countries get little in return. Drug companies spend far more money on advertising and marketing than they do on research, far more on research for lifestyle drugs (for conditions like impotence and hair loss) than for lifesaving drugs, and almost no money on diseases that afflict hundreds of millions of poor people, such as malaria. It is a matter of simple economics: companies direct their research where the money is, regardless of the relative value to society. The poor can’t pay for drugs, so there is little research on their diseases, no matter what the overall costs.

A “me-too” drug, for example, which nets its manufacturer some portion of the income that otherwise accrues only to the company that dominates a niche, may be highly profitable, even if its value to society is quite limited. Similarly, companies raced to beat the human genome project in order to patent genes such as that associated with breast cancer. The value of these efforts was minimal: the knowledge was produced just a little sooner than it would have been otherwise. But the cost to society was enormous: the high price that Myriad, the patent holder, places on genetic tests (between $3,000 and $4,000) may well mean that thousands of women who would otherwise have been tested, discovered that they were at risk, and taken appropriate remediation, will die instead.

There is an alternative way of financing and incentivizing research that, at least in some instances, could do a far better job than patents, both in directing innovation and ensuring that the benefits of that knowledge are enjoyed as widely as possible: a medical prize fund that would reward those who discover cures and vaccines. Since governments already pay the cost of much drug research directly or indirectly, through prescription benefits, they could finance the prize fund, which would award the biggest prizes for developers of treatments or preventions for costly diseases affecting hundreds of millions of people.

Especially when it comes to diseases in developing countries, it would make sense for some of the prize money to come from foreign assistance budgets, as few contributions could do more to improve the quality of life, and even productivity, than attacking the debilitating diseases that are so prevalent in many developing countries. A scientific panel could establish a set of priorities by assessing the number of people affected and the impact on mortality, morbidity, and productivity. Once the discovery is made, it would be licensed.

Of course, the patent system is itself a prize system, albeit a peculiar one: the prize is temporary monopoly power, implying high prices and restricted access to the benefits that can be derived from the new knowledge. By contrast, the type of prize system I have in mind would rely on competitive markets to lower prices and make the fruits of the knowledge available as widely as possible. With better-directed incentives (more research dollars spent on more important diseases, less money spent on wasteful and distorted marketing), we could have better health at lower cost.

That said, the prize fund would not replace patents. It would be part of the portfolio of methods for encouraging and supporting research. A prize fund would work well in areas in which needs are well known – the case for many diseases afflicting the poor – allowing clear goals to be set in advance. For innovations that solve problems or meet needs that have not previously been widely recognized, the patent system would still play a role.

The market economy and the profit motive have led to extremely high living standards in many places. But the health care market is not an ordinary market. Most people do not pay for what they consume; they rely on others to judge what they should consume, and prices do not influence these judgments as they do with conventional commodities. The market is thus rife with distortions. It is accordingly not surprising that in the area of health, the patent system, with all of its distortions, has failed in so many ways. A medical prize fund would not provide a panacea, but it would be a step in the right direction, redirecting our scarce research resources toward more efficient uses and ensuring that the benefits of that research reach the many people who are currently denied them. ... 81/English
User avatar
Family Elder
Posts: 1608
Joined: Wed Aug 11, 2004 3:00 pm


Re: Problems with patents

Postby NHE » Tue Mar 13, 2007 2:35 pm

For further reading on this subject area, interested folks might wish to check out some of my book recommendations on the Reading Nook forum.
    Selling Sickness: How the World’s Biggest Pharmaceutical Companies are Turning Us All Into Patients. Ray Moynihan and Alan Cassels. Nation Books, 2005.

    Overdosed America: The Broken Promise of American Medicine by Dr. John Abramson. Harper Perennial, 2005.

User avatar
Volunteer Moderator
Posts: 4477
Joined: Sat Nov 20, 2004 4:00 pm


Postby lyndacarol » Tue Mar 13, 2007 4:29 pm

On the recommendations of NHE, I read Selling Sickness and Overdo$ed America. These are excellent! I highly recommend them!
User avatar
Family Elder
Posts: 3382
Joined: Thu Dec 22, 2005 4:00 pm

Postby LisaBee » Wed Mar 14, 2007 9:45 pm

A few months ago, I caught on TV the tail end of a presentation by some CEO of a big pharmaceutical company - I'm sorry I can't remember his name or which company, so this isn't a very official citation of anything.

He was talking about the great frontier of pharmaceuticals - of turning diseases that are fatal into chronic diseases. He declared that the goal was turn cancer into a "chronic disease". Not a goal of a cancer cure, mind you, but that a disease currently terminal could be rendered "chronic".

It sent a chill down my spine. That is essentially advocating prolonging sickness, so people with a previously terminal disease can live longer so they can take more medication, and what a growth industry that will be.

I hope my growing cynicism of the industry is misplaced, but I'm afraid that it isn't.
User avatar
Family Elder
Posts: 177
Joined: Sat Apr 30, 2005 3:00 pm
Location: Florida

Return to General Discussion


  • Related topics
    Last post

Who is online

Users browsing this forum: ElliotB

Contact us | Terms of Service